LOTTE BIOLOGICS Targets Global Expansion in ADC CDMO Market with Consecutive Participation 

in CPHI Frankfurt and World ADC San Diego

■ Strengthening global competitiveness through dual-site infrastructure and proven quality excellence

▲ [Photo] LOTTE BIOLOGICS booth at CPHI Worldwide 2025 in Frankfurt, Germany

Seoul, South Korea – November 3, 2025 – LOTTE BIOLOGICS (CEO James Park) announced its participation in World ADC San Diego 2025, held from November 3 to 6 in San Diego, USA, following the successful completion of CPHI Worldwide 2025 in Frankfurt, Germany.

From October 28 to 30 (local time), LOTTE BIOLOGICS showcased its capabilities at CPHI Worldwide2025 in Frankfurt, where the company held over 40 partnership meetings with potential global clients, expanding its global business network through active engagement. Notably, the company also signed a Letter of Intent (LOI) with SK pharmteco to strengthen strategic collaboration in the Antibody-Drug Conjugate (ADC) market, further demonstrating its growing presence as a global ADC CDMO.

Building on this momentum, LOTTE BIOLOGICS will continue its outreach at World ADC San Diego 2025, held from November 3 to 6 (local time), to reinforce its position as a next-generation ADC CDMO.

Now in its 16th year, World ADC is the world’s largest conference dedicated to the ADC field, drawing more than 1,400 global experts and industry leaders to share the latest technological and research insights. LOTTE BIOLOGICS, joining the event for the second consecutive year, aims to further strengthen its global competitiveness as an emerging leader in ADC development and manufacturing.

On the first day (November 3), Dr. Kern Chang, Chief Technology Officer at LOTTE BIOLOGICS, will deliver a presentation titled “Accelerating Bioconjugate Development & Manufacturing with LOTTE BIOLOGICS’ ADC Platform.”

His presentation will introduce:

• LOTTE BIOLOGICS’ state-of-the-art manufacturing infrastructure, covering the entire ADC value chain from development through GMP production;
• The company’s proprietary hydrophilic linker technology, SoluFlex Link™;
• A flexible and efficient system that supports rapid transitions from clinical to commercial manufacturing.

These technological elements are recognized for enabling enhanced speed, stability, and quality in ADC candidate development and production.

James Park, CEO of LOTTE BIOLOGICS, stated,

“With our dual-site global manufacturing infrastructure in the U.S. and Korea and end-to-end services, LOTTE BIOLOGICS will help reduce development risks and accelerate commercialization for our partners,” . “Building on the strong global interest and collaborative momentum confirmed at CPHI, we will further strengthen our presence as a global ADC CDMO through this year’s World ADC.”